BusiNETvs - 28/05/2009 - Jean-Michel Métry, Groupe AARDEX

Page 1

Innovation dans le suivi thérapeutique des patients BusiNETvs Dr. Jean-Michel Métry CEO, AARDEX Group (CH)

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX®


MEMS I 1987

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Breaking the downward spiral

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


MEMS system Medication Event Monitoring System (MEMS速)

Events recording and storage

MEMS速 6 BusiNETvs, Sierre, May 28th, 2009

Communication device

MEMS速 Reader Copyright AARDEX速

Internet

www.viewcompliance.com


Aardex Group products & strengths

Basic feedback to the patient Nothing

INFORMATION

Number of openings during the day Time since last dose taken Compliance index

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


MEMS 7

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


SCL Detection scheme

Mechanical action

Contact between 2 conductive layers

Manipulation

Signal detection

Prototype Noise BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速

Pill out


SCL: development status

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Research prototype 2009

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Technology platform

New IP

CORE IP AARDEX Group BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation and taxonomy

Non acceptance 1.0

Perfect adherence

0.8 0.7 0.4

0.5

0.6

Percent

0.9

Treatment discontinuation

0

100

200

Days Source: AARDEX (Pharmionic database)

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速

300

PKC: N ~ 20,000 patients


Innovation and regulation: EU-ABC project

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation and networking iAdherence

Research community

Heathcare systems & Drug regulators

Insurers

Pharma industry

Health care providers End users

Physician Pharmacist Nurse

Patients Families Patients associations

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速

B. Vrijens, Feb 2008


Innovation and communication

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation and publication

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation and positioning

AAG Unique position

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation: competitor analysis Identification of current and future competitors MWV & Stora Enso (e-blister) B & OM (Bang & Olufsen Medicom Helping Hand device) GlowCap (new in the market with a simple concept) e-Pill pure gadget company

Competitor Positioning Map (considering relevant variables)

Information AAG

B & OM

MWV

As low as possible CoG Maximum information

Strora Enso Price e-Pill

GlowCap

Innovation axis BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation: modelling and simulation Validation: Cutoff criteria (based on the ROC Curve): 0.1 Number of neighbours: 20

Persistent

Predicted based on the algorithm

Non Persistent

Sensitivity: 79% Specificity: 62% Positive Predictive Value: 29% Negative Predictive Value: 94%

BusiNETvs, Sierre, May 28th, 2009

Actual Observation

Persistent

Non Persistent

106 (62%) (94%)

7 (21%) (6%)

65 (38%) (71%)

27 (79%) (29%)

171 (100%)

34 (100%)

113 (100%) 92 (100%) 205

Poor executers: it’s good to intervene anyway Good executers: it’s difficult to predict their non-persistence based on their quality of executions

Copyright AARDEX®


Innovation and new business model Business Models

What & Why: product and value proposition EM and modeling and/or simulation for the CT and intervention for the broader market with medAmigo intervention

Where: target groups/customers and possible market segments From the pharmaceutical companies to the patients including third party payers, patients’ organizations,…

How: possible strategy for market entry and positioning Large pharma launch for new products and/or re-launch of existing products with innovative interactive packaging concept.

Who: position in the value network and necessary partnerships Mostly be the end user who is, in our case the patient

How to deliver: internal value chains and market distribution channel Via our existing channels and potentially new partners

How much: cost structures and revenue generation mechanism For every dollar spent at least one back

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX®


Innovation and market opportunities


Innovation and market potential Clinical trial market (measurement no intervention) Target customers: Pharmaceutical companies Users: Health care professionals and patients

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Innovation and evolution (cycles) 3.2 Interventional market (medAmigo intervention) Target customers: Pharmaceutical companies, insurers,‌ Users: Health care professionals to patients

Market potential In US$ is going to be billions of US$

BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEXÂŽ


THANK YOU! BusiNETvs, Sierre, May 28th, 2009

Copyright AARDEX速


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.